ArticlePLoS currents2010
HLA-B*5701 testing to predict abacavir hypersensitivity.
Article in PLoS currents, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.The pharmacogenomics journal · 2022Pooled it
- Eco-friendly nanoscale recognition: a MIP-based electrochemical sensor for selective determination of abacavir in pharmaceutical and serum samples.Analytical and bioanalytical chemistry · 2026Article
- Knowledgeable Language Models as Black-Box Optimizers for Personalized Medicine.... International Conference on Learning Representations · 2026Article
- Concordance of an in-house 2-steps PCR-SSP and nanopore sequencing forFrontiers in genetics · 2025Article
- Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study.BMC research notes · 2024Article
- Review
- Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye.Current HIV research · 2024Article
- Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services?Pharmacy (Basel, Switzerland) · 2023Article
- Factors Influencing Immune Restoration in People Living with HIV/AIDS.Journal of clinical medicine · 2022Article
- Distribution ofFrontiers in pharmacology · 2022Article
- Risk Factors, Screening, Diagnosis, and Treatment of Osteoporosis in HIV-Infected Adults in an HIV Primary Care Clinic.The Canadian journal of hospital pharmacy · 2022Article
- Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection.Current infectious disease reports · 2022Review
- Article
- PromotingInternational journal of environmental research and public health · 2020Review
- Mechanistic insights into antiretroviral drug-induced liver injury.Pharmacology research & perspectives · 2020Review
- Transcriptomic Responses to Ivacaftor and Prediction of Ivacaftor Clinical Responsiveness.American journal of respiratory cell and molecular biology · 2019Article
- Drug hypersensitivity in HIV infection.Current opinion in allergy and clinical immunology · 2019Review
- Translating Pharmacogenetics and Pharmacogenomics to the Clinic: Progress in Human and Veterinary Medicine.Frontiers in veterinary science · 2019Review
- The Collaborative African Genomics Network (CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV and HIV-tuberculosis infection in sub-Saharan Africa.AAS open research · 2018Article
- Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.The pharmacogenomics journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Abacavir-induced hypersensitivity reaction has been associated with the presence of the major histocompatibility complex class I allele HLA-B*5701. A screening test for the HLA-B*5701 allele can assist clinicians to identify patients who are at risk of developing a hypersensitivity reaction to abacavir.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.